https://www.activebiotech.com/sv/presentation/active-biotechs-presentation-pa-solebury-trout-european-biotech-investor-days-2021/2021-05-02T14:28:11+02:00https://www.activebiotech.com/sv/presentation/active-biotechs-presentation-pa-aktiedagen-4-maj-2021-aktiespararna/2021-05-04T15:26:13+02:00https://www.activebiotech.com/sv/presentation/kapitalmarknadsdag-2020/2020-11-24T15:00:47+01:00https://www.activebiotech.com/sv/presentation/active-biotechs-presentation-pa-abgsc-life-science-summit-25-maj-2021/2021-05-28T11:17:02+02:00https://www.activebiotech.com/sv/presentation/active-biotech-vd-helen-tuvesson-presenterar-vid-redeye-life-science-day-2020/2020-12-01T15:37:04+01:00https://www.activebiotech.com/sv/presentation/active-biotech-vd-helen-tuvesson-presenterar-vid-redeye-growth-day-2021/2021-06-07T14:14:48+02:00https://www.activebiotech.com/sv/presentation/active-biotech-presenterar-pa-aktiespararnas-aktiedag-lund/2021-09-28T15:04:14+02:00https://www.activebiotech.com/sv/presentation/active-biotechs-presentation-pa-aktiespararnas-aktiedagen-lund-31-januari-2022/2022-01-31T16:54:18+01:00https://www.activebiotech.com/sv/presentation/active-biotech-redeye-intervju-med-vd-helen-tuvesson/2022-08-22T10:10:34+02:00https://www.activebiotech.com/sv/presentation/7132/2022-09-27T09:21:15+02:00https://www.activebiotech.com/sv/presentation/hur-bygger-man-ett-lo%cc%88nsamt-life-science-bolag-aktiedagen-27-januari-2021/2021-01-27T16:18:24+01:00https://www.activebiotech.com/sv/presentation/active-biotech-redeye-intervju-med-vd-helen-tuvesson-2/2022-11-29T12:54:33+01:00https://www.activebiotech.com/sv/presentation/active-biotech-vd-helen-tuvesson-presenterar-vid-redeye-fight-cancer-2023/2023-01-23T09:20:26+01:00https://www.activebiotech.com/sv/presentation/active-biotech-presentation-pa-redeye-growth-day-1-juni-2023/2023-06-07T15:08:02+02:00https://www.activebiotech.com/sv/presentation/aktiedagen-i-lund-9-oktober-2023/2023-10-10T12:46:16+02:00https://www.activebiotech.com/sv/presentation/redeye-videointervju-med-vd-helen-tuvesson/2023-11-16T10:25:18+01:00https://www.activebiotech.com/sv/presentation/vd-helen-tuvesson-presenterar-pa-redeye-life-science-day-2023-23-november/2023-11-27T10:59:27+01:00https://www.activebiotech.com/sv/presentation/huvudprovare-rebekka-schneider-kramann-presenterar-den-kliniska-planen-och-positioneringen-av-tasquinimod-i-myelofibros-audiocast-sammandrag/2023-12-01T09:32:54+01:00https://www.activebiotech.com/sv/presentation/financialhearings-com-audiocast-2023-den-kliniska-planen-och-positioneringen-av-tasquinimod-i-myelofibros/2023-12-01T09:31:29+01:00https://www.activebiotech.com/sv/presentation/investing-in-oncology-forum-10-april-2024/2024-04-10T14:44:03+02:00https://www.activebiotech.com/sv/presentation/intervju-med-prof-dr-axel-glasmacher-oberoende-styrelseledamot-pa-active-biotech/2026-07-01T11:35:38+02:00https://www.activebiotech.com/sv/presentation/infocusintervju-med-vd-helen-tuvesson-pa-redeye-growth-day-30-maj-2024/2024-06-03T10:45:17+02:00https://www.activebiotech.com/sv/presentation/redeye-videointervju-med-vd-helen-tuvesson-2/2024-10-30T15:50:41+01:00https://www.activebiotech.com/sv/presentation/infocusintervju-med-vd-helen-tuvesson-pa-redeye-technology-life-science-day-2024/2024-12-05T13:52:01+01:00https://www.activebiotech.com/sv/presentation/intervju-med-lucia-masarova-assistant-professor-pa-md-anderson-cancer-center/2026-07-01T11:34:32+02:00https://www.activebiotech.com/sv/presentation/redeye-intervju-med-vd-helen-tuvesson-och-cmo-erik-vahtola/2025-05-13T10:55:36+02:00https://www.activebiotech.com/sv/presentation/redeye-active-biotech-intervju-redeye-pratar-med-vd-helen-tuvesson-om-nyemissionen/2025-10-24T14:45:27+02:00https://www.activebiotech.com/sv/presentation/stora-aktiedagarna-stockholm-25-november-2025/2025-11-26T09:30:46+01:00https://www.activebiotech.com/sv/presentation/redeye-active-biotech-intervju-redeye-pratar-med-vd-helen-tuvesson-om-nulaget/2026-06-24T16:58:32+02:00https://www.activebiotech.com/sv/presentation/active-biotech-foretagspresentation/2026-07-03T09:20:48+02:00https://www.activebiotech.com/sv/presentation/biostock-intervju-med-helen-tuvesson-active-biotech-kommenterar-forsta-doseringen-i-uppdaterad-myelofibrosstudie/2026-08-17T12:04:25+02:00